Conatus Pharmaceuticals (CNAT): Jumping On The Zika Train - FBR
- Wall St. drops on bleak GE outlook; Microsoft blunts losses
- British American Tobacco Offers to Acquire Remaining Shares of Reynolds American (RAI) for $56.50/Share
- UPDATE: AT&T (T) in Advanced Talks to Acquire Time Warner (TWX) - DJ
- Rockwell Automation (ROK) Said to Attract Takeover Interest from Schneider Electric - Source
- General Electric (GE) Tops Q3 EPS by 2c; Updates FY16 EPS Outlook
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Conatus Pharmaceuticals (NASDAQ: CNAT) after research published in the journal Nature Medicine by scientists at the National Institutes of Health (NIH) and its collaborators showed that emricasan, a small molecule, pan caspase inhibitor in Phase II development for liver cirrhosis (LC) by Conatus Pharmaceuticals, is effective in reducing the ability of Zika virus (ZIKV) to kill brain cells.
The analyst has no knowledge of any further clinical activities with emricasan in ZIKV; however, the results pose an intriguing and positive development for Conatus, as interest in emricasan by the broader medical community could accelerate its path to regulatory approval.
No change to the price target of $16.
Shares of Conatus Pharmaceuticals closed at $2.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Axovant Sciences (AXON) Risk/Reward 'Massively Skewed to the Upside' - Baird
- RBC Capital Raises Price Target on Danaher (DHR) Following 'Clean' 3Q Report
- SunTrust Raises Price Target on E*TRADE Financial (ETFC) to $31 Following Solid 3Q
Create E-mail Alert Related CategoriesAnalyst Comments, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!